The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Continue advancing our pipeline candidates, with several key updates in 2025, including CTX112™ in oncology and autoimmune ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

'Mad Money' host Jim Cramer weighs in on stock including: Lincoln Electric, Caesars Entertainment, CRISPR, and Seagate. This ...

Professor Kevin J. Zwezdaryk and Chandler H. Monk discuss CRISPR and diagnostics, focusing on the development of a portable ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...